Merck Hdac Research, LLC, based in Boston, MA, is a research-focused organization specializing in the development of innovative therapeutic solutions. The company is engaged in the exploration of histone deacetylase (HDAC) inhibitors, which play a crucial role in epigenetic regulation and have potential applications in oncology and other therapeutic areas. By leveraging advanced research methodologies, Merck Hdac Research aims to contribute significantly to the field of medicine, enhancing treatment options and improving patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

12 Patents

#169 in Boston, MA

#1,546 in Massachusetts

#25,557 in US

#48,163 in the World

Boston, MA, United States of America

Merck Hdac Research, LLC

Forward Citations = 90

8 inventors:

Thomas Allen Miller (12 out of 54 patents)

Victoria M Richon (9 out of 28 patents)

Judy H Chiao (6 out of 11 patents)

4. Nicholas G Bacopoulos (3 out of 3 patents)

5. Carolyn M Paradise (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Merck Hdac Research, LLC. Retrieved from https://idiyas.com/company/merck-hdac-research

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]